Results build on LATITUDE study and robust body of evidence supporting investigational use.
GSK announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager from Chimagen Biosciences.
GSK today announced positive results from the registrational phase I/II ARROS-1 trial
GSK today announced positive results from the registrational phase I/II ARROS-1 trial
Longer survival achieved with fewer severe treatment-related side effects versus comparator...
New presentation offers convenient administration of GSK's shingles vaccine
Phase III trial to start in September 2026
If approved, Jemperli could eliminate the need for chemotherapy, radiation, and surgery for some patients.
First global approval for Hibsago
Superiority data from LATA together with OPERA findings add to the clinical and real-world evidence base for long-acting injectable Cabenuva
Investment further integrates company into world-class ecosystem of biomedical research, patient care and academia
ARTEMIS-011, a phase III study conducted for China, met its primary endpoint of progression-free survival in relapsed osteosarcoma
Positive Week 48 data from the phase IIIb VOGUE study reinforce Dovato as an effective treatment option with fewer medicines than Biktarvy
Next-generation design aims to address key efficacy and tolerability challenges of treating ROS1-positive NSCLC.
VOGUE is the first head-to-head, randomised daily orals study comparing 2-drug regimen Dovato with 3-drug regimen Biktarvy
If approved, a single booster dose could help protect individuals who were previously vaccinated with Bexsero
GSK plc (LSE/NYSE: GSK) today provides an update on the CALM-1 and CALM-2 phase III clinical trials
GSK plc today announced completion of its acquisition of Nuvalent, Inc. , a Boston-based clinical-stage biopharmaceutical company.